drugset / Trial / NCT05212857
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
Oligo-metastatic prostate cancer (OMPCa) is considered as an intermediated state between localized and poly-metastatic disease. Various retrospective studies and prospective clinical trials are carrying out to validate whether patients with OMPCa could benefit from local treatment for both primary and metastatic lesions. The investigators here to conduct a unique clinical trial which OMPCa patients were confirmed by conventional imaging, and received a long-term enhanced systemic therapy accompanied by tumor-directed therapy.
Timeline
- Start
- 2022-04
- Primary completion
- 2024-02
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Abiraterone acetate | Small molecule | — | Oral |
| Background | Apalutamide | Small molecule | — | Oral |
| Background | Degarelix | Other / unclassified | — | Subcutaneous |
| Background | Enzalutamide | Other / unclassified | — | Oral |
| Background | Goserelin | Other / unclassified | — | Subcutaneous |
| Background | Leuprolide | Other / unclassified | — | Subcutaneous |
| Background | Triptorelin | Other / unclassified | — | Subcutaneous |